🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesPost-prandial glucose control — May 2025

Post-prandial glucose control — May 2025

carl_compliance Thu, Mar 19, 2026 at 12:39 PM 4 replies 632 viewsPage 1 of 1
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Mar 19, 2026 at 12:39 PM#1

A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

The bit I cannot resolve on my own is why A1C lags the way it does, and what to look at in the meantime if you want to know sooner.

If the honest answer is that nobody knows, that is a useful answer and I would rather have it.

13 8labquiet_amy, emily_PDX, Dr.SleepRoch and 10 others
Reply Quote Save Share Report
Dr.SleepRoch
Senior Member
1,123
5,678
Apr 2024
Rochester, MN
Mar 19, 2026 at 12:54 PM#2
carl_compliance said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

My labs after 3 months on glycaemic control: A1C 5.4%, fasting glucose 79 mg/dL, fasting insulin 8 uIU/mL. My endo says these are "textbook perfect."

For context, my baseline A1C was 7.3% and fasting glucose was 114 mg/dL. The improvement has been dramatic and consistent.

12 7kim_atl_prep, sarah_TO, wendy_avl and 9 others
Reply Quote Save Share Report
RetaRick_CA
VIP Member
2,012
9,876
Jan 2024
California
Mar 19, 2026 at 1:09 PM#3
Dr.SleepRoch said:
My labs after 3 months on glycaemic control: A1C 5.4%, fasting glucose 79 mg/dL, fasting insulin 8 uIU/mL.

Glycemic variability as the key metric for glycaemic control success: my coefficient of variation (CV) on CGM dropped from 41% to 21%. Target is <36%, with <30% being ideal.

Why this matters more than average glucose: large glucose swings cause oxidative stress, endothelial damage, and promote advanced glycation end-products (AGEs). A flat glucose line at 95 mg/dL is metabolically healthier than oscillating between 60 and 160, even if the average is the same.

Last edited: Mar 19, 2026 at 2:09 PM
11 6DadBodDave, AmyNC_wife, SkepticalSean and 8 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
josh_phd_bmore
Member
389
1,678
Jul 2024
Baltimore, MD
Mar 19, 2026 at 1:25 PM#4
carl_compliance said:
A1C went from 7.4 to 5.6 over nine months and my prescriber was more interested in the fasting insulin, which I did not expect.

This matches mine closely enough to be worth saying so out loud. The detail I would add is minor and it is already implied above.

Last edited: Mar 19, 2026 at 3:25 PM
10 5KarenAZ_mom, zoe_NC, Dr.ObesityLA and 7 others
Reply Quote Save Share Report
andrew_nyc
Member
534
2,345
Apr 2024
New York, NY
Mar 19, 2026 at 2:47 PM#5

From the other side of the consultation, briefly.

Complete metabolic panel trending on glycaemic control — sharing because comprehensive data helps everyone:

TestBaselineMonth 3Month 6Month 12
Glucose (fasting)1141049082
Insulin (fasting)2012105
HOMA-IR4.54.01.81.3
Uric Acid8.76.45.75.0

The insulin resistance improvement (HOMA-IR) is what my endo focuses on most. Going from 4.5 to near 1.0 is a metabolic transformation.

Last edited: Mar 19, 2026 at 7:47 PM
9 4JessicaM_2024, TomFromTexas, mike.trainer_LA and 6 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register